ArticleJournal of clinical periodontology2025
TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis.
Article in Journal of clinical periodontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06715176 (Prognostic Utility of TREM-1 Pathway in Predicting Treatment Outcomes in Patients With Grades B and C Periodontitis), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Utility of TREM-1 Pathway in Predicting Treatment Outcomes in Patients With Grades B and C Periodontitis
Who cites it
1 citing paper in PubMed.
- TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis.Journal of clinical periodontology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study investigated the diagnostic potential of salivary triggering receptor expressed on myeloid cells (TREM)-1, peptidoglycan recognition protein 1 (PGLYRP1) and interleukin (IL)-1β for periodontitis patients and their ability to predict treatment outcome.
methodsSystemically healthy, non-smokers with gingivitis (n = 31), stage III periodontitis (34 grade B: n = 34, grade C: n = 24) and healthy controls (n = 34) were recruited. Periodontitis patients (n = 42) underwent non-surgical periodontal treatment. Saliva was collected at baseline (T0) and post-treatment (T1, T3, T6). Biomarkers were measured using immunoassays. Periodontitis patients were categorised into responders (n = 19) and non-responders (n = 23) based on the number of residual pockets ≥ 5 mm with bleeding on probing at T6.
resultsTREM-1 was higher in periodontitis than in gingivitis and health, and in periodontitis grade B than in gingivitis (p < 0.05). PGLYRP1 and IL-1β were higher in periodontitis and gingivitis compared to controls (p < 0.01). All biomarkers discriminated periodontitis from health (AUC ≥ 0.9) with high sensitivity (82.1%-92.8%) and specificity (83.3%-88.9%). TREM-1 differentiated periodontitis from gingivitis (AUC = 0.72) with high sensitivity (92.8%) but low specificity (58.1%). Baseline biomarkers did not predict treatment outcome (AUC ≤ 0.61), while T1 levels showed moderate potential (AUC ≥ 0.71).
conclusionsSalivary TREM-1 pathway biomarkers offer diagnostic value for periodontitis, are modulated by therapy but show limited ability to predict treatment outcome. STUDY REGISTRATION: The study has been registered in ClinicalTrials.gov (ID: NCT06715176, 4 December 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.